BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory "legalization of marijuana, gun control legislation, legalization of gambling, and restriction of television violence" (Miller et al., 2013, p. 135). Phase 2 presented an inoculation message relative to each participant's measured attitudes from Phase 1. The participants were divided into two groups, including the inoculation group and the control group. The questionnaire the participants received also gauged both their perceived threat and affect toward the attack messages. In Phase 3, each group was also given an attack message using either high-controlling or low-controlling language, and again, to evaluate the levels of perceived threat and affect. The study concluded that support